Cooperative Group Research Endeavors in Small-cell Lung Cancer: Current and Future Directions

Current and Future Directions

Randeep Sangha; Primo N. Lara, Jr.; Alex A. Adjei; Paul Baas; Hak Choy; Laurie E. Gaspar; Glenwood Goss; Nagahiro Saijo; Joan H. Schiller; Everett E. Vokes; David R. Gandara


Clin Lung Cancer. 2009;10(5) 

In This Article


Through their capacity to offer a wide range of scientific and patient resources, multi-institutional cooperative groups have a vital responsibility to ensure that significant strides in SCLC research continue to be made. As many SCLC trials have traditionally been underpowered, the importance of large collaborative research efforts to maximize accrual cannot be overemphasized. In addition, the trend to incorporate translational science studies into each trial offers an avenue to discern the underlying mechanisms of SCLC chemotherapy resistance and to perhaps develop future prognostic and predictive biomarker profiles. However, considerable work remains in order to overcome 2 decades of stagnant gains in SCLC management. The focus has shifted to first optimizing the delivery of known effective treatments, such as thoracic irradiation in LSSCLC, before expanding upon the paradigm so that therapeutic advances are built on a solid foundation. Moreover, novel targeted agents will certainly be added to the SCLC treatment armamentarium, ideally based on strong preclinical rationale and an appropriate "druggable" target, but to date, no targeted therapy has been approved for patients with SCLC. Indeed, the ongoing and planned research endeavors of the cooperative group system are essential to ensure that the future progress for SCLC management remains encouraging.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.